STAT News

STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more

Once promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel better

Par STAT News

1 minute de lecture
Partager
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more

Vous avez une actualité à partager avec le secteur événementiel ?

Envoyez un communiqué de presse ou une information et touchez des milliers de professionnels de l'événementiel.

Nous contacter→

Plus dans Health Tech

Articles connexes